Agilisium Invests in AI to Transform Pharma, Biotech & Medical Tech Companies

According to the company, the forward-deployment model combines deep Life Sciences domain expertise with AI engineering and data science capability.

Chennai-based Agilisium, a life sciences-focused AI services company, has invested INR 50 crore to help pharmaceutical, biotech, and medical technology enterprises operationalize artificial intelligence.

As part of this effort, the company has launched Forward Deployment Experts (FDX), a new professional standard built around four key dimensions: domain, AI, technology, consultative solution systems, and process thinking.

According to a statement issued by the city-based company, the investment would reskill and deploy Agilisium's global workforce of more than 1,000 professionals as embedded AI transformation partners.

According to the company, the forward-deployment model combines deep Life Sciences domain expertise with AI engineering and data science capability.

Agilisium professionals collaborate closely with scientists, clinical teams, and commercial stakeholders to design, deploy, and continuously operate AI-driven capabilities.

Commenting on the occasion, Agilisium Founder and CEO Raj Babu said, "The biggest constraint in AI adoption in Life Sciences is no longer technology; it is talent. The companies that will lead Life Sciences in the next decade will not be the ones that simply purchase AI models. They will be the ones that embed AI capability deep inside their organisations."

He continued, "At Agilisium, our advantage comes from the compounding institutional and domain knowledge we have built by focusing exclusively on Life Sciences."

Stay tuned for more such updates on Digital Health News